Pharsight

Drugs that contain Glecaprevir; Pibrentasvir

1. Mavyret patents expiration

MAVYRET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8648037 ABBVIE INC Macrocyclic proline derived HCV serine protease inhibitors
Jan, 2032

(7 years from now)

US8937150 ABBVIE INC Anti-viral compounds
May, 2032

(8 years from now)

USRE48923 ABBVIE INC Crystal forms
May, 2035

(11 years from now)

US9321807 ABBVIE INC Crystal forms
Jun, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028937 ABBVIE INC Anti-viral compounds
Jun, 2030

(6 years from now)

US10039754 ABBVIE INC Anti-viral compounds
Jun, 2030

(6 years from now)

US9586978 ABBVIE INC Anti-viral compounds
Nov, 2030

(6 years from now)

US10028937

(Pediatric)

ABBVIE INC Anti-viral compounds
Dec, 2030

(6 years from now)

US10039754

(Pediatric)

ABBVIE INC Anti-viral compounds
Dec, 2030

(6 years from now)

US9586978

(Pediatric)

ABBVIE INC Anti-viral compounds
May, 2031

(7 years from now)

US8648037

(Pediatric)

ABBVIE INC Macrocyclic proline derived HCV serine protease inhibitors
Jul, 2032

(8 years from now)

US8937150

(Pediatric)

ABBVIE INC Anti-viral compounds
Nov, 2032

(8 years from now)

US11484534 ABBVIE INC Methods for treating HCV
Mar, 2034

(10 years from now)

US10286029 ABBVIE INC Method for treating HCV
Mar, 2034

(10 years from now)

US10286029

(Pediatric)

ABBVIE INC Method for treating HCV
Sep, 2034

(10 years from now)

US11484534

(Pediatric)

ABBVIE INC Methods for treating HCV
Sep, 2034

(10 years from now)

USRE48923

(Pediatric)

ABBVIE INC Crystal forms
Nov, 2035

(11 years from now)

US9321807

(Pediatric)

ABBVIE INC Crystal forms
Dec, 2035

(11 years from now)

US11246866 ABBVIE INC Solid pharmaceutical compositions for treating HCV
Jun, 2036

(12 years from now)

US11246866

(Pediatric)

ABBVIE INC Solid pharmaceutical compositions for treating HCV
Dec, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 10, 2028
Pediatric Exclusivity (PED) Dec 10, 2028

Market Authorisation Date: 03 August, 2017

Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg; Treatment of chronic hepatitis c virus (hcv)...

Dosage: TABLET;ORAL

More Information on Dosage

MAVYRET family patents

Family Patents